Abivax (AAVXF) Accounts Payables (2021 - 2026)

Abivax has reported Accounts Payables for 6 years, with the latest figure at $34.6 million in Q1 2026.

• On a quarterly basis, Accounts Payables fell 41.89% year-over-year to $34.6 million in Q1 2026; TTM through Mar 2026 was $34.6 million, a 41.89% decrease from a year earlier, with the FY2025 full-year figure at $43.7 million, down 6.66% from the prior year.
• Accounts Payables was $34.6 million for Q1 2026 at Abivax, down from $43.7 million in the prior quarter.
• The five-year high for Accounts Payables was $65.1 million in Q2 2025, with the low at $15.8 million in Q4 2022.
• Average Accounts Payables over 5 years is $42.8 million, with a median of $43.7 million recorded in 2025.
• The sharpest annual moves came in 2023 and 2026: Accounts Payables soared 221.8% in 2023, then tumbled 41.89% in 2026.
• Over 5 years, Accounts Payables stood at $15.8 million in 2022, then jumped by 221.8% to $50.8 million in 2023, then slipped by 7.83% to $46.8 million in 2024, then declined by 6.66% to $43.7 million in 2025, then fell by 20.95% to $34.6 million in 2026.
• The last three Accounts Payables figures came in at $34.6 million (Q1 2026), $43.7 million (Q4 2025), and $35.1 million (Q3 2025), per Business Quant data.